PIPELINE

MaaT Pharma develops a global solution based on a safe and standardized process for autologous fecal microbiotherapy.

Entered clinical stage mid-2016.

MaaT001: INNOVATIVE LIVE FROZEN INOCULUM SUSPENSION.

Our ambition is to develop a drug to treat dysbiosis related diseases characterized by:

  • Patented formulation
  • Stability and viability of the inoculum
  • Global safety and convenience for the patients
  • Outsourced, standardized and reproducible process
MaaT002: INNOVATIVE DEVICE FOR STOOL COLLECTION AND STORAGE. CONVENIENT FOR DUODENAL OR RECTAL ADMINISTRATION.

Our ambition is to facilitate the access to FMT to clinicians characterized by:

  • No contamination by the environment
  • No environmental contamination by the inoculum
  • Stability and viability of the inoculum
  • Global safety and convenience for care-holders
  • Standardization and reproducibility of the process
  • Wide access to the method for everyone everywhere